{"filing":{"accession_number":"0001493152-26-047762","cik":"0001006028","ticker":"PURE","company_name":"PURE BIOSCIENCE, INC.","form":"8-K","filing_date":"2026-10-20","report_date":"2026-10-15","primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1006028/000149315226047762/form8-k.htm"},"events":[{"id":36422,"run_id":33586,"accession_number":"0001493152-26-047762","anchor_item_number":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"The filing discloses a private placement financing completed on October 15, 2026, in which PURE Bioscience issued 10,183,486 shares of common stock at $0.0545 per share to accredited investors, raising $555,000. The shares were issued pursuant to a Securities Purchase Agreement under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D—a classic unregistered equity issuance. Item 3.02 explicitly incorporates the private placement details, confirming this is an unregistered sale of equity securities. The substantial share count and dilutive nature of the issuance make this material to investors assessing the registrant's capital structure and ownership.","company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","filing_date":"2026-10-20","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":40832,"accession_number":"0001493152-26-047762","item_number":null,"item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses a private placement financing completed on October 15, 2026, in which PURE Bioscience issued 10,183,486 shares of common stock at $0.0545 per share to accredited investors, raising $555,000. The shares were issued pursuant to a Securities Purchase Agreement under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D—a classic unregistered equity issuance. Item 3.02 explicitly incorporates the private placement details, confirming this is an unregistered sale of equity securities. The substantial share count and dilutive nature of the issuance make this material to investors assessing the registrant's capital structure and ownership.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T20:16:41.337556+00:00","company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","filing_date":"2026-10-20"}]}